Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.092

Jean-Francois Baurain , Hye Sook Chon , Jessica Thomes Pepin , Michael Sundborg , Michael Gold , Byoung-Gie Kim , Stephanie Blank , Ji-Hong Liu , Michael McCollum , Masahiko Mori , Goda Jonuskiene , Kathleen Moore , Zoltan Novak , Pedro Luis Ramos Guette , Charles Andreé Joseph de Pádua , Marta Gil Martin , Matthew Kowgier , Paula Michelle del Rosario , Shannon Westin , Els Van Nieuwenhuysen

引用次数: 0

查看原文本刊更多论文

杜伐单抗加卡铂/紫杉醇后，再用杜伐单抗加或不加奥拉帕利作为子宫内膜癌的一线治疗：DUO-E/GOG-3041/ENGOT-EN10试验中按错配修复状态划分的总生存期和其他次要疗效指标

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy